The 2027 Prior Authorization Deadline Is a 2026 Governance Decision
CMS-0057-F's compressed decision windows and the AI arms race in claims adjudication mean health systems and payers must settle oversight now, not at go-live.
Health & Clinical Operationsbriefings.
AI in health systems, clinical labs, and hospital operations.
The Governance Frameworks Already Exist. Health Systems Aren't Using Them for Agentic AI
Regulators admit they are behind on agentic AI, but ISO 42001 and NIST AI RMF already give governance committees the accountability structure they need now.
The Governance Gap Hospitals Can No Longer Delegate to IT
Health systems are running hundreds of AI tools with few having named oversight authority, and agentic AI is already outrunning the approval process.
AI Features Are Becoming the New EHR Lock-In
As ambient documentation and agentic tools embed into EHR platforms, health systems are trading interface lock-in for AI lock-in, with little contractual protection.
The Convergence Gap in AI Life Sciences Regulation
Regulators describe AI, digital health, and clinical trial law as converging, but FDA, UK, and Chinese actions show the frameworks are still moving on separate, misaligned tracks.
The Merger Clause Nobody's Underwriting
Hospital M&A due diligence checklists have no line item for inherited AI model inventories, and two live deals show why that gap is now material.
Healthcare's AI Governance Has No Evidence Layer
A new benchmark finds 91% of healthcare organizations cannot verify their own AI governance, exposing a policy-to-proof gap just as CMS deadlines force more AI into clinical workflows.
Digital Pathology AI Scales Into a Validation Framework Built for Assays, Not Algorithms
As AI-assisted digital pathology expands across CLIA-certified labs, the real decision is whether existing CAP validation checklists can actually capture algorithmic performance.
When AI Writes the Prescription
Utah's AI-issued acne prescriptions test the line between clinical decision support and practicing medicine, with implications for every health system's AI procurement.
Revenue Cycle AI Has No Certified Standard
Provider and payer AI tools now optimize claims and denials against each other, but no HIPAA, ONC, or federal rule actually governs that decision logic.
Ambient Scribes Are Outgrowing Their Oversight
Ambient AI documentation tools are expanding into agentic clinical workflows that sit outside ONC certification, just as health system boards show limited AI governance capacity.
AI Governance's Real Fault Line Is Classification, Not Geography
Divergence in AI rules across the US, EU, and China is driven less by geography than by conflicting definitions of what counts as a regulated AI function.
The Clawback Guarantee Is Not a Governance Program
Vendors are offering financial guarantees against payer clawbacks for AI-driven documentation, but that is insurance, not the audit evidence compliance committees actually need.
Clinical AI's Accuracy Question Was Never the Whole Question
FDA's own framework gaps show interaction risk matters as much as accuracy, but the on-premise architecture fix now circulating is a contested proposal, not a settled control.
Clinical AI Already Has Rules. Most Deployments Sit Outside Them.
The real governance decision for health systems is not whether to build an AI committee, but which deployments already sit inside CLIA, ONC certification, or HIPAA, and which sit in open air.
The Clinical AI Governance Gap Is Structural, Not Accidental
The regulatory perimeter around clinical AI is contested by design, and the same gap is opening upstream in drug development.
Agentic AI Is Colliding With Information Blocking Law
As EHR vendors build AI stickiness into their platforms, federal rules moving toward autonomous data access expose an unresolved question of who authorizes the agent.
The Breach Behind Healthcare's AI Interoperability Push
A 20 million-person Oracle Health breach exposes a certification gap: AI riding on certified EHR pipes answers to no one in particular.
Health AI Is Straining Categories, Not Just Rules
US data provenance, UK product classification, and Chinese jurisdictional scope are all cracking under AI health tools that don't fit pre-AI regulatory taxonomy.
The Governance Gap Belongs to the Deployer, Not the Regulator
Hospitals and pharma functions adopting generative AI now carry governance obligations that device and drug frameworks were never built to cover.
The Benchmarking Gap FDA Hasn't Closed
Nature Medicine's new framework for evaluating generalist medical AI outpaces FDA's device-modification tools, leaving capability-tier governance to buyers.
The Real Medical LLM Bottleneck Is Proof, Not Selection
Clinical AI adoption stalls less on model choice and more on whether teams can prove, on demand, that human oversight actually functioned.
The NeoGenomics-Indica Labs Deal Is a Vendor Governance Question, Not Just an Infrastructure One
As a decade-long AI pathology vendor relationship scales across a national lab network, the open question for lab leadership is contractual, not technical.
Your Patients Are Uploading Health Data Into a Regulatory Gap
Life sciences firms building patient-facing AI tools are relying on a HIPAA and FDA perimeter that consumer health AI routinely sits outside.
Prior Authorization Agents Are Outrunning Oversight
CMS-0057-F is pushing payers and providers to automate prior authorization with AI agents faster than anyone has defined who governs the handoff between them.
The Prior Authorization Arms Race Needs a Referee, and CMS Just Became It
As payers and providers both deploy AI against each other in prior authorization, CMS's interoperability mandate is emerging as the only shared check on escalation.
Prior Authorization Is Already a Clinical AI Governance Regime
While experts debate a new regulatory framework for clinical AI, CMS-0057-F already imposes auditable timeliness and explainability controls on AI deciding prior authorization.
The Prior Authorization Deadline Is Already a Build Problem
CMS-0057-F's compressed decision timelines put AI-driven prior authorization and denial management on the critical path, with real accountability gaps still unresolved.
The Guidance Cannot Outrun the Model
FDA and EU regulators are structurally too slow to govern AI at the pace it changes, so life sciences compliance leaders must build internal governance now.
The Claims Pipeline's Real Risk Isn't AI vs. AI. It's No One Verifying Either Side
Providers and payers are both automating the claims lifecycle with AI, but governance visibility hasn't kept pace with either deployment.
When the Scribe Starts Talking to Patients
Ambient AI vendors are moving from note-drafting scribes to patient-facing intake agents, and most health systems haven't re-run the risk assessment for that leap.
The Governance Gap FDA's Rulemaking Won't Reach
FDA is still asking questions about generative AI in medicine while health systems already run it inside clinical workflows unmonitored.
The Patchwork Problem in Clinical AI Oversight
State-by-state AI rules are creating divergent liability and oversight standards for clinical AI, forcing health systems to govern to the strictest jurisdiction.
The Escalation Contract Patient-Facing AI Actually Needs
Penn Medicine's AI-moderated epilepsy messaging pilot shows the real governance work is designing the human review loop, not picking the model.
When Health Data Leaves the Regulated Perimeter
FDA's wellness classification determines more than marketing claims. It decides whether patient data uploaded to AI tools carries any regulatory protection at all.
When the Scribe Starts Asking Questions
Ambient AI scribes are being redeployed as interactive patient intake agents, and most hospital governance policies still classify them by their original, lower-risk use case.
